[Therapy for children with Shiga toxin-E. coli-associated hemolytic uremic syndrome].
Hemolytic uremic syndrome(HUS) is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute nephropathy. Clinical features and outcome of children with HUS initiated by infections with Shiga toxin(Stx)-producing strains of Escherichia coli(E. coli) infection are different from those of patients with the other forms of HUS or thrombotic thrombocytopenic purpura(TTP). Childhood Stx-E. coli-associated HUS usually recovers spontaneously and dose not require specific treatments including plasma therapy. In contrast, a general consensus has been achieved that plasma exchange or infusion should always be tried in adult HUS/TTP to minimize the risk of death or long-term sequelae. In this paper, we briefly reviewed therapy for patients with Stx-E. coli-associated HUS.
Ito
Katsumi
K
Department of Pediatric Nephrology, Tokyo Women's Medical University.
Hattori
Motoshi
M
Matsumoto
Naoko
N
D000328:Adult; D002648:Child; D004927:Escherichia coli Infections; D019453:Escherichia coli O157; D005759:Gastroenteritis / Q000150:complications / Q000382:microbiology; D006463:Hemolytic-Uremic Syndrome / Q000209:etiology / Q000628:therapy*; D006801:Humans; D010951:Plasma Exchange; D022621:Shiga Toxin
D022621:Shiga Toxin